Rhythm Pharmaceuticals Profit Margin

The latest profit margin for RYTM is -87.83% as of June 2026. That compares with -117.98% in the prior-year period — up 25.6% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Rhythm Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, RYTM's profit margin moved from -117.98% to -87.83% — a 25.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rhythm Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, RYTM currently prints -87.83% for profit margin, while the sector average sits near 13.89%. That is roughly 732.2% below the sector mean. Large gaps often invite a closer look at Rhythm Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Rhythm Pharmaceuticals converts resources into returns. At -87.83%, RYTM may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -117.98% in the prior-year period — up 25.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RYTM's profit margin (-87.83%), review year-over-year change from -117.98%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.